Clomipramine hydrochloride, the active ingredient of Anafranil, is a tricyclic antidepressant used for obsessive-compulsive disorder and other conditions requiring specialist treatment. Anafranil…
Clomipramine hydrochloride, the active ingredient of Anafranil, is a tricyclic antidepressant used for obsessive-compulsive disorder and other conditions requiring specialist treatment. Anafranil tablets increase serotonin and norepinephrine activity in the central nervous system.
Anafranil is a medicine containing clomipramine hydrochloride, a tricyclic antidepressant used mainly for obsessive-compulsive disorder and other specialist indications.
The dose of Anafranil is decided individually, taking age, other medicines, and health conditions into account. Treatment often begins cautiously, followed by adjustment according to response and adverse effects.
The timing can be adapted to tolerability. A dose that causes sleepiness may be scheduled later in the day, while a dose that causes activation or insomnia may be better taken earlier. This adjustment belongs in the prescribing plan.
Do not crush or alter a modified-release formulation unless the prescriber or dispensing instructions specifically allow it. Changing the release pattern can expose the body to the active substance too quickly.
Anafranil contains clomipramine hydrochloride, also called clomipramine. It belongs to the tricyclic antidepressant class. This medicine changes the handling of specific neurotransmitters in the brain and spinal cord, with a strong effect on serotonin reuptake and additional effects on norepinephrine reuptake [1].
Clomipramine has a long clinical history in obsessive-compulsive disorder. Anafranil tablets are taken by mouth, and treatment is normally adjusted gradually to balance symptom control with tolerability.
Clomipramine hydrochloride is the hydrochloride salt of clomipramine. After oral administration, the body converts part of it into desmethylclomipramine, an active metabolite with a greater influence on norepinephrine pathways. This combination helps explain both its therapeutic effects and some adverse effects, such as dry mouth, constipation, drowsiness, sweating, and changes in heart rate [2].
The medicine may influence several receptor systems besides serotonin and norepinephrine transporters. Anticholinergic activity can cause blurred vision, urinary difficulty, dry mouth, and constipation. Histamine receptor activity can contribute to sedation and increased appetite.
Clomipramine inhibits the reuptake of serotonin in nerve cells. More serotonin remains available in the synaptic space, allowing repeated signalling between neurons. It also inhibits norepinephrine reuptake, although its serotonin effect is usually more prominent.
Serotonin helps regulate mood, anxiety, repetitive thoughts, sleep, and emotional processing. Norepinephrine contributes to alertness, concentration, motivation, and stress responses. Changing these systems takes time because downstream neural circuits gradually adapt to altered neurotransmitter signalling.
Clomipramine differs from selective serotonin reuptake inhibitors because it affects several receptor systems and has a stronger interaction with norepinephrine transport than a purely serotonin-selective medicine. That broader activity can help some people with OCD, while also producing more anticholinergic, sedating, cardiovascular, and sexual adverse effects.
The WHO classification places clomipramine among non-selective monoamine reuptake inhibitors. Its established use in OCD is reflected in specialist treatment guidance, including recommendations from NICE for pharmacological treatment alongside psychological approaches where appropriate [3].
Anafranil is used mainly for obsessive-compulsive disorder, where unwanted intrusive thoughts and repetitive behaviours cause significant distress or interfere with daily activities. Clomipramine may also be prescribed for depressive illness and panic disorder when a clinician considers its pharmacological profile appropriate.
Its use depends on the diagnosis, symptom pattern, previous treatment, coexisting conditions, and other medicines. OCD often requires a longer treatment period than a short episode of low mood because symptoms may improve gradually and relapse prevention can require continued therapy.
| Clinical use | Expected treatment focus | Response pattern |
|---|---|---|
| Obsessive-compulsive disorder | Fewer obsessions and compulsions | Improvement commonly develops gradually over several weeks |
| Depression | Mood, sleep, motivation, and anxiety symptoms | Mood changes may emerge progressively rather than after the first doses |
| Panic disorder | Reduced panic frequency and anticipatory anxiety | Early activation can occur before sustained benefit |
Clomipramine is not intended to provide immediate relief during an acute panic attack. It works through regular treatment, not through occasional use immediately before distress.
The medicine may also be used in specialist practice for selected anxiety-related or pain-related conditions. Those uses depend on local prescribing decisions and are not interchangeable with the approved indication for every patient.
Several avoidable problems can reduce benefit or increase risk:
One practical point is easy to miss: stopping smoking can alter the metabolism of some psychiatric medicines, although the effect on clomipramine is not identical to that seen with every antidepressant. Any major change in smoking status should be mentioned during medication review.
Another is the danger of duplicate anticholinergic treatment. Some antihistamines, bladder medicines, and sleep products can intensify dry mouth, constipation, blurred vision, confusion, and urinary retention.
Anafranil is not suitable for everyone. This medicine is not for you if you have had a serious allergic reaction to clomipramine or another tricyclic antidepressant, or if you are recovering from a recent heart attack unless a specialist has made a specific decision.
Extra caution or specialist review is needed with:
Monoamine oxidase inhibitors must not be combined with clomipramine. A medically supervised interval is required when switching between these medicines. Other serotonergic drugs, including some antidepressants, tramadol, lithium, linezolid, and certain migraine medicines, can increase the risk of serotonin syndrome.
Medicines that prolong the QT interval can add to the risk of dangerous arrhythmias. This includes some antipsychotics, antiarrhythmics, macrolide antibiotics, and antimalarial agents. The interaction list can include asenapine, arsenic trioxide, and artemether, depending on the full treatment regimen and the patient’s cardiac risk.
Anagrelide can add cardiac rhythm concerns. Apixaban and other anticoagulants can increase bleeding risk when combined with antidepressants that affect platelet function. The combination does not automatically mean treatment is impossible, but it requires a prescriber-led assessment of bleeding, heart rhythm, kidney function, and other medicines.
Do not stop a long-term course abruptly. Sudden withdrawal may cause nausea, sweating, sleep disturbance, irritability, anxiety, headache, or a return of the original symptoms.
Anafranil may not be appropriate if you have serious heart problems, unexplained fainting, seizures, bipolar disorder, narrow-angle glaucoma, difficulty passing urine, severe liver disease, or a high risk of falls. Tell a clinician if you are pregnant, breastfeeding, older or frail, or taking several medicines. Do not use it with monoamine oxidase inhibitors, and ask for a medication review before combining it with serotonergic medicines, medicines that affect heart rhythm, anticoagulants, or sedating products.
Common effects include dry mouth, constipation, nausea, sweating, tremor, blurred vision, dizziness, drowsiness, fatigue, headache, appetite changes, and difficulty sleeping. Sexual dysfunction and delayed orgasm can occur. Some people gain weight during longer treatment, while others notice reduced appetite during the first weeks.
The anticholinergic effects can be practical rather than dramatic. Constipation may appear before a patient connects it with the medicine. Blurred vision can make reading difficult, while urinary hesitancy can be more troublesome in men with prostate enlargement.
Clomipramine may lower blood pressure when standing. Rise slowly from bed or a chair, especially during dose changes. Palpitations, fainting, chest pain, or an irregular heartbeat require prompt medical assessment because tricyclic antidepressants can affect cardiac conduction and rhythm .
Urgent medical attention is needed for:
Serotonin syndrome is uncommon but serious. It can involve agitation, sweating, diarrhoea, fever, tremor, muscle stiffness, and rapidly changing blood pressure or heart rate, especially after combining serotonergic medicines.
Alcohol can intensify sedation and impair judgement. Combining Anafranil with alcohol is therefore a poor choice, especially during dose changes or when the medicine already causes dizziness.
Clomipramine is distinguished by its strong serotonin reuptake inhibition and broader receptor activity. SSRIs act more selectively on serotonin reuptake and are often considered first-line options for many anxiety and depressive disorders. Other tricyclic antidepressants share some of Anafranil’s receptor effects but may be chosen for different symptom patterns.
| Treatment approach | Main pharmacological feature | Main limitation |
|---|---|---|
| Clomipramine | Strong serotonin reuptake inhibition with additional norepinephrine and receptor effects | More anticholinergic, sedating, and cardiac effects |
| SSRI class | More selective serotonin reuptake inhibition | Can cause nausea, sexual dysfunction, insomnia, or emotional blunting |
| Other tricyclic antidepressant class | Monoamine reuptake inhibition with varied receptor activity | Tolerability and overdose risk require careful prescribing |
For OCD, clomipramine may be considered when an SSRI has not provided sufficient improvement or has caused unacceptable problems. Some patients experience more dry mouth, constipation, sweating, sedation, or dizziness with clomipramine than with an SSRI. Others find its broader activity helpful when OCD occurs with depression or marked anxiety.
No antidepressant works equally well for every person. The choice depends on previous response, suicide risk, seizure history, heart disease, glaucoma, urinary symptoms, pregnancy status, and the interaction profile of existing medicines.
In clinical practice, doctors usually assess clomipramine by tracking function rather than expecting a sudden change in mood. For OCD, useful signs may include spending less time on rituals, resisting reassurance-seeking more often, or experiencing intrusive thoughts with less distress.
A prescriber may increase the dose slowly because adverse effects can appear before the full therapeutic effect. This approach is also useful for older adults and people taking several medicines.
Cardiac history matters. A clinician may review blood pressure, pulse, previous fainting, family history of sudden cardiac death, and other medicines that influence cardiac conduction before selecting a tricyclic antidepressant.
Psychological treatment remains relevant in OCD. Exposure and response prevention can be combined with medicine when clinically suitable. Anafranil may reduce symptom intensity enough for a person to engage more effectively with structured therapy.
Clomipramine is not a medicine to judge after one or two doses. A fair assessment requires regular use over the period set by the prescriber, unless serious adverse effects appear earlier.
The course length depends on the diagnosis, relapse history, response, and adverse effects. OCD and recurrent depression may require maintenance treatment after symptoms improve, while the duration is reviewed periodically rather than fixed for every patient. NICE guidance published in 2013 supports continuing treatment in selected patients when relapse risk remains substantial. Long-term use requires periodic review of mood, cardiac symptoms, constipation, urinary function, weight, and other medicines. Follow-up should also reassess whether the benefits continue to outweigh adverse effects.
There is no single time that suits every patient because clomipramine may cause either drowsiness or activation. A prescriber may prefer evening administration when sedation is prominent, or earlier dosing when night-time insomnia occurs. Medsafe’s 2025 medicine information describes dose timing as part of the individual treatment plan. Take it consistently and avoid changing the schedule repeatedly without discussing the effect on sleep, alertness, and daily activities.
Seizures, fainting, severe palpitations, chest pain, serious allergic swelling, severe confusion with fever and rigidity, or suicidal thoughts require urgent assessment. Sudden eye pain with coloured halos and inability to pass urine also need prompt medical attention. The FDA Anafranil prescribing information revised in 2024 highlights seizures, cardiac effects, and serious psychiatric changes among clinically important warnings. Do not take another dose while awaiting urgent advice when a severe reaction is suspected, unless emergency clinicians direct otherwise.
Clomipramine is a tricyclic antidepressant with strong serotonin reuptake inhibition, additional norepinephrine effects, and activity at several other receptors. An SSRI acts more selectively on serotonin reuptake and may cause fewer anticholinergic and cardiac effects, though sexual dysfunction, nausea, and sleep changes remain possible. The European Medicines Agency’s 2013 guideline on clinical investigation of medicinal products in depression supports choosing treatment according to the indication, patient factors, and interaction risk. For OCD, the decision often reflects previous response and tolerability rather than one medicine being universally preferable.
Clomipramine can cause drowsiness, blurred vision, dizziness, reduced alertness, or slower reactions. These effects may be strongest during initiation or after a dose increase. The FDA’s 2024 Anafranil prescribing information warns that clomipramine may impair alertness. Do not drive or operate machinery if you feel sedated, faint, visually impaired, confused, or unable to concentrate reliably.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
Masterton, took Anafranil as prescribed for obsessive thoughts over several weeks. He described less time spent checking, although dry mouth and morning dizziness were troublesome at first. His prescriber adjusted the timing, and the dizziness became easier to manage.
Masterton Over several weeks 6 Oct 2026Hastings, used clomipramine during treatment for panic symptoms and low mood. She reported improved sleep after the early weeks but disliked sweating and constipation. Regular fluids and a review of other medicines helped, but the treatment still required careful monitoring.
Hastings After the early weeks 15 Oct 2026Taupō, noticed fewer compulsive rituals after sustained treatment. The first days brought restlessness and difficulty concentrating at work, so he avoided driving until the effect became predictable. He found the benefit worthwhile but did not consider the medicine easy to tolerate.
Taupō After sustained treatment 21 Oct 2026Ashburton, stopped treatment after developing pronounced palpitations and blurred vision. Medical review led to a different plan. Her experience shows why new cardiac or visual symptoms should not be managed by simply continuing and hoping they disappear.
Ashburton 4 Nov 2026
